JP2019514401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514401A5 JP2019514401A5 JP2018557875A JP2018557875A JP2019514401A5 JP 2019514401 A5 JP2019514401 A5 JP 2019514401A5 JP 2018557875 A JP2018557875 A JP 2018557875A JP 2018557875 A JP2018557875 A JP 2018557875A JP 2019514401 A5 JP2019514401 A5 JP 2019514401A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence shown
- effector
- nucleic acid
- shmir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 45
- 150000007523 nucleic acids Chemical class 0.000 claims 45
- 102000039446 nucleic acids Human genes 0.000 claims 45
- 239000012636 effector Substances 0.000 claims 41
- 230000000295 complement effect Effects 0.000 claims 21
- 241000700721 Hepatitis B virus Species 0.000 claims 12
- 239000002679 microRNA Substances 0.000 claims 8
- 238000011144 upstream manufacturing Methods 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108020005065 3' Flanking Region Proteins 0.000 claims 2
- 108020005029 5' Flanking Region Proteins 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229960001997 adefovir Drugs 0.000 claims 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000980 entecavir Drugs 0.000 claims 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332245P | 2016-05-05 | 2016-05-05 | |
| US62/332,245 | 2016-05-05 | ||
| PCT/AU2017/050413 WO2017190197A1 (en) | 2016-05-05 | 2017-05-05 | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019514401A JP2019514401A (ja) | 2019-06-06 |
| JP2019514401A5 true JP2019514401A5 (enExample) | 2020-04-30 |
Family
ID=60202535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557875A Pending JP2019514401A (ja) | 2016-05-05 | 2017-05-05 | Ｂ型肝炎ウイルス（ｈｂｖ）感染を治療するための試薬およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11535851B2 (enExample) |
| EP (1) | EP3452595A4 (enExample) |
| JP (1) | JP2019514401A (enExample) |
| KR (1) | KR102358280B1 (enExample) |
| CN (1) | CN109415733A (enExample) |
| AU (2) | AU2017260580B2 (enExample) |
| CA (1) | CA3023185A1 (enExample) |
| PH (1) | PH12018502320A1 (enExample) |
| RU (2) | RU2021113126A (enExample) |
| SG (1) | SG11201809753YA (enExample) |
| WO (1) | WO2017190197A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109415733A (zh) * | 2016-05-05 | 2019-03-01 | 贝尼泰克生物制药有限公司 | 用于治疗乙型肝炎病毒(hbv)感染的药剂及其使用 |
| EP3881850B1 (en) * | 2018-11-16 | 2024-07-17 | Tokyo Metropolitan Institute of Medical Science | Composition for inhibiting replication of hepatitis b virus |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| RU2217161C2 (ru) * | 1997-08-26 | 2003-11-27 | Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.) | Способ лечения вирусного гепатита |
| CA2921821A1 (en) * | 2001-07-12 | 2003-01-23 | University Of Massachusetts | In vivo production of small interfering rnas that mediate gene silencing |
| CN1257284C (zh) | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| US8575327B2 (en) * | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| WO2006069064A2 (en) | 2004-12-22 | 2006-06-29 | Nucleonics, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| WO2008147430A2 (en) * | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Microrna-formatted multitarget interfering rna vector constructs and methods of using the same |
| CN101603042B (zh) * | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| US20120142764A1 (en) * | 2009-06-05 | 2012-06-07 | Dai-Wu Seol | Multi-Cistronic shRNA Expression Cassette for Suppressing Single or Multiple Target Genes |
| US20130267429A1 (en) * | 2009-12-21 | 2013-10-10 | Lawrence Livermore National Security, Llc | Biological sample target classification, detection and selection methods, and related arrays and oligonucleotide probes |
| SMT201900317T1 (it) * | 2010-10-28 | 2019-09-09 | Benitec Biopharma Ltd | Trattamento dell’hbv |
| EA202090994A1 (ru) * | 2011-06-30 | 2020-08-31 | Эрроухэд Фармасьютикалс, Инк. | Композиции и способы ингибирования экспрессии генов вируса гепатита в |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| CA2892529C (en) * | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| WO2014117050A2 (en) | 2013-01-26 | 2014-07-31 | Mirimus, Inc. | Modified mirna as a scaffold for shrna |
| CN103088026A (zh) | 2013-02-01 | 2013-05-08 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 抗乙型肝炎病毒人工miRNA及其组合 |
| PL243776B1 (pl) * | 2013-09-02 | 2023-10-09 | Inst Chemii Bioorganicznej Polskiej Akademii Nauk | Cząsteczka kwasu nukleinowego, kaseta ekspresyjna, wektor ekspresyjny, komórka eukariotycznego gospodarza i zastosowanie cząsteczki kwasu nukleinowego w terapii chorób wywoływanych ekspansją trójnukleotydowych powtórzeń typu CAG |
| EP3292202A4 (en) * | 2015-05-06 | 2019-04-10 | Benitec Biopharma Limited | REAGENTS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION AND USE THEREOF |
| CN109415733A (zh) * | 2016-05-05 | 2019-03-01 | 贝尼泰克生物制药有限公司 | 用于治疗乙型肝炎病毒(hbv)感染的药剂及其使用 |
-
2017
- 2017-05-05 CN CN201780040430.8A patent/CN109415733A/zh active Pending
- 2017-05-05 EP EP17792296.0A patent/EP3452595A4/en not_active Withdrawn
- 2017-05-05 US US16/098,759 patent/US11535851B2/en active Active
- 2017-05-05 JP JP2018557875A patent/JP2019514401A/ja active Pending
- 2017-05-05 AU AU2017260580A patent/AU2017260580B2/en not_active Ceased
- 2017-05-05 CA CA3023185A patent/CA3023185A1/en active Pending
- 2017-05-05 SG SG11201809753YA patent/SG11201809753YA/en unknown
- 2017-05-05 RU RU2021113126A patent/RU2021113126A/ru unknown
- 2017-05-05 KR KR1020187035341A patent/KR102358280B1/ko not_active Expired - Fee Related
- 2017-05-05 WO PCT/AU2017/050413 patent/WO2017190197A1/en not_active Ceased
- 2017-05-05 RU RU2018142797A patent/RU2748806C2/ru active
-
2018
- 2018-11-05 PH PH12018502320A patent/PH12018502320A1/en unknown
-
2022
- 2022-09-27 AU AU2022241489A patent/AU2022241489A1/en not_active Abandoned
- 2022-11-18 US US18/056,929 patent/US20230093951A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005521393A5 (enExample) | ||
| RU2013124422A (ru) | Лечение hbv-инфекции | |
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| JP2018519835A5 (enExample) | ||
| JP2012136542A5 (enExample) | ||
| JP2015518713A5 (enExample) | ||
| JP2019519219A5 (enExample) | ||
| JPWO2022067130A5 (enExample) | ||
| JP2015518710A5 (enExample) | ||
| JP2013532952A5 (enExample) | ||
| JP2015519057A5 (enExample) | ||
| JP2015518712A5 (enExample) | ||
| JP2016522674A5 (enExample) | ||
| JP2015523855A5 (enExample) | ||
| JP2015518711A5 (enExample) | ||
| JP2018512876A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| JP2007527244A5 (enExample) | ||
| JP2018513668A5 (enExample) | ||
| JP2008283975A5 (enExample) | ||
| JP2018512041A5 (enExample) | ||
| JP2009102380A5 (ja) | ｄｓＲＮＡを含む、ウイルス感染又は望ましくない細胞増殖によって媒介されるか又は誘導される病気又は疾患の治療用組成物 | |
| JP2006526394A5 (enExample) | ||
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| JP2018517704A5 (enExample) |